The House Judiciary Committee announced that it is investigating whether Pfizer intentionally delayed releasing COVID vaccine results to influence the 2020 presidential election, following allegations from a senior Pfizer executive.
The probe will look into alleged claims from Dr. Philip Dormitzer, Pfizer’s former Global Head of Vaccines Research and Development, that vaccine testing was deliberately slowed ahead of Election Day in 2020, according to a press release by the committee Thursday.
Republican House Judiciary Committee Chairman Jim Jordan sent letters to both Dormitzer and Pfizer Chairman and CEO Dr. Albert Bourla. (RELATED: New Tool Lets You Search CDC Advisors’ Big Pharma Ties)
🚨 HUGE 🚨
New Information Suggests Senior Pfizer Executives Conspired to Delay COVID-19 Vaccine Clinical Testing to Influence 2020 Election.
One exec was so scared about this being investigated that he asked to be relocated to Canada!
MASSIVE SCANDAL uncovered by @Jim_Jordan. pic.twitter.com/pZKLAz1Wmx
— House Judiciary GOP 🇺🇸🇺🇸🇺🇸 (@JudiciaryGOP) May 15, 2025
Operation Warp Speed, the U.S. government project launched on May 15, 2020 during the first Trump administration in response to COVID-19, aimed to accelerate vaccine development and distribution within 12 to 18 months. By combining military logistics, scientific research, and industry efforts, the initiative sought to produce 100 million vaccine doses by the end of 2020, with Pfizer, Moderna, and Johnson & Johnson as key developers.
New reporting has fueled speculation that Pfizer delayed the release of its final Phase 3 trial results and the announcement of the vaccine’s 95% efficacy — holding off until November 18, 2020, just 15 days after the election — to avoid giving an edge to Trump’s re-election bid.
The Wall Street Journal reported in March that Manhattan prosecutors were investigating a tip that Dormitzer, who left Pfizer in 2021, told colleagues at a subsequent job at rival drug company GSK that the timing of the vaccine announcement “wasn’t a coincidence.”
The House Judiciary Committee wrote to GSK requesting more information regarding the allegations on April 9.
GSK responded on April 16, stating that in November 2024, shortly after Trump’s election, Dormitzer approached a human resources representative to discuss a potential relocation abroad.
The letter notes that Dormitzer appeared upset and expressed concern he could be investigated by the incoming Trump administration over his role in developing Pfizer’s COVID-19 vaccine. According to the HR representative, when asked about the timing of his relocation request, Dormitzer remarked, “Let’s just say it wasn’t a coincidence, the timing of the vaccine.”
Exclusive: Lawmakers are investigating whether Pfizer waited to share results of the Covid vaccine in 2020 until after that year’s presidential election https://t.co/2CFxNLCJgB
— The Wall Street Journal (@WSJ) May 15, 2025
GSK also informed the committee that Dormitzer told employees, “In late 2020, the three most senior people in Pfizer R&D were involved in a decision to deliberately slow down clinical testing so that it would not be complete prior to the results of the presidential election that year.” (RELATED: Doc Who Revived Zombie Virus From Frozen Corpse Now Has Keys To Fauci’s Old Agency)
In his letters to Bourla and Dormitzer, Chairman Jordan requested that Pfizer provide documents and communications, including emails and texts, between Bourla, Dormitzer and Pfizer staff regarding COVID-19 vaccine data from March 1, 2020, to the present day.
Additionally, the committee is seeking records of Pfizer’s interactions with several federal agencies about vaccine testing during that period.
The press release by the committee notes, “Although it is unclear which Pfizer R&D employees were involved with Dr. Dormitzer in the decision to delay clinical testing, Dr. Dormitzer conveyed to GSK that Pfizer’s CEO was not aware of the delay.”
The House Judiciary Committee did not respond to a request for comment in time for publication.
Read the full article here
